BBNX Healthcare

Beta Bionics, Inc.

$15.10-5.03%

Price as of close on Nov 3, 2026 · Financials updated Oct 6, 2026

Basics

Sector: Healthcare
Industry: Medical Devices
Country: United States
Market cap: 814.6M USD
Enterprise value: 470.9M USD
Full-time employees: 420

Overall health

Strength: growing faster than most peersgrowing faster than peers
Strength: lower risk than most peers: more short-term liquidity and less debt relative to equitylower risk: more liquidity and less debt vs equity
Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Ranks #552 of 1,157 healthcare companies (top 48%)

See how it ranks against its peers

Worth knowing

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Beta Bionics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Growing fast, still losing money. Revenue grew faster than 90% of peers, at an operating loss.
Revenue grew faster than 90% of peers, but the business runs at an operating loss (margin -70%).

StockQuotient Score

53/ 100

Oct 5 53 → Nov 4 53

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-10.7%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-17.2%

Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-9.0%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield37.7%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

93/100

Strong

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

12-month revenue up 8.0%

Why

Stronger than most peers on:

▲ 3-yr revenue
▲ Revenue growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Still loss-making, but the loss per share narrowed33% base weight · Z-score 0.29Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth724.3%

Yahoo Finance fallback · SEC figure unavailable or out of date · 3 fiscal years to Dec 2025Outlier capped at sector 5th/95th percentile33% base weight · Z-score 8.59Sector median: 0.0584 · MAD: 0.0840

Revenue growth52.5%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 4.77Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

19/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Operating margin
▼ ROA
▼ ROIC

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-69.8%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -6.31Sector median: 0.0706 · MAD: 0.1217

Return on assets-25.0%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -4.96Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-30.9%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -3.55Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin58.3%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-28.5%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

2/3 inputs reported · Partial data

Since last quarter: No major change

Why

Stronger than most peers on:

▲ Current ratio
▲ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

BetaUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.6250 · MAD: 0.3380

Current ratio8.88×

SEC filings · latest balance sheetReported value33% base weight · Z-score 4.54Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.03×

Yahoo Finance fallback · no standard SEC debt tagReported value33% base weight · Z-score 0.96Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Beta Bionics

Is Beta Bionics getting weaker?: Its latest SEC filing (Jul 29, 2026) showed no major changes. Its overall score is unchanged at 53/100 since Oct 28, 2026.
How is Beta Bionics valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -10.7% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -10.7% vs peers 1.5% (weaker than 100% of peers).
Is Beta Bionics growing?: Yes, faster than most of its peers. Growth scores 93/100 against 1,393 healthcare peers. 3-year revenue growth 724.3% vs a peer median of 5.8% (stronger than 95% of peers).3-year revenue growth 724.3% vs peers 5.8% (stronger than 95% of peers).
How profitable is Beta Bionics?: Less profitable than most of its peers. Profitability scores 19/100 against 1,393 healthcare peers. Operating margin -69.8% vs a peer median of 7.1% (weaker than 85% of peers).Operating margin -69.8% vs peers 7.1% (weaker than 85% of peers).
How risky is Beta Bionics?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 8.88× vs a peer median of 2.59× (stronger than 85% of peers).Current ratio 8.88× vs peers 2.59× (stronger than 85% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Jul 29, 2026 · compared with the quarter ended Mar 31, 2026

No major changes

Worth watching: Beta Bionics is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.

	Previous quarter	Latest quarter	Change
Revenue (12 months)	110.2M USD	119.0M USD	+8.0%
Net income (12 months)	−66.4M USD	−73.0M USD	+9.8%
Operating margin	-70.1%	-69.8%	+0.4 pts
Free cash flow (12 months)	−61.1M USD	−61.4M USD	+0.5%
Cash	30.2M USD	44.3M USD	+46.7%
Shares outstanding	44.6M	45.0M	+1.0%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Medical Devices · 33 companies

Valuations in Medical Devices are near the bottom of their range since 2016.

7% of months since 2016 were valued lower than now.
4% of companies are in the most expensive fifth of their own price-to-sales history.
Over 24 months, company values −8% and earnings +33% (medians): earnings grew faster than prices.
Median price-to-sales is +20% vs the whole market, against a usual +109%.

2016Shaded: most expensive fifth of its range2026

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2023	FY 2024	FY 2025	Change
Gross margin	52.6%	55.1%	55.4%	▲ 0.3 pts
Operating margin	-298.9%	-69.5%	-71.5%	▼ 2.0 pts
Net margin	-367.6%	-84.1%	-73.0%	▲ 11 pts
Return on assets (ROA)	-40.1%	-36.6%	-22.3%	▲ 14 pts
Return on equity (ROE)	—	—	-25.5%	—
Free cash flow margin	-273.8%	-79.3%	-56.1%	▲ 23 pts
Current ratio	9.77×	6.29×	8.66×	▲ 38%
Quick ratio	9.65×	5.66×	7.96×	▲ 41%

BBNX price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: growing faster than most peersgrowing faster than peers

Strength: lower risk than most peers: more short-term liquidity and less debt relative to equitylower risk: more liquidity and less debt vs equity

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Ranks #552 of 1,157 healthcare companies (top 48%)

See how it ranks against its peers

Worth knowing

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Beta Bionics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Growing fast, still losing money. Revenue grew faster than 90% of peers, at an operating loss.

Revenue grew faster than 90% of peers, but the business runs at an operating loss (margin -70%).

Questions investors ask about Beta Bionics

Is Beta Bionics getting weaker?

Its latest SEC filing (Jul 29, 2026) showed no major changes. Its overall score is unchanged at 53/100 since Oct 28, 2026.

How is Beta Bionics valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -10.7% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -10.7% vs peers 1.5% (weaker than 100% of peers).

Is Beta Bionics growing?

Yes, faster than most of its peers. Growth scores 93/100 against 1,393 healthcare peers. 3-year revenue growth 724.3% vs a peer median of 5.8% (stronger than 95% of peers).3-year revenue growth 724.3% vs peers 5.8% (stronger than 95% of peers).

How profitable is Beta Bionics?

Less profitable than most of its peers. Profitability scores 19/100 against 1,393 healthcare peers. Operating margin -69.8% vs a peer median of 7.1% (weaker than 85% of peers).Operating margin -69.8% vs peers 7.1% (weaker than 85% of peers).

How risky is Beta Bionics?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 8.88× vs a peer median of 2.59× (stronger than 85% of peers).Current ratio 8.88× vs peers 2.59× (stronger than 85% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

110.2M USD

119.0M USD

+8.0%

Net income (12 months)

−66.4M USD

−73.0M USD

+9.8%

Operating margin

-70.1%

-69.8%

+0.4 pts

Free cash flow (12 months)

−61.1M USD

−61.4M USD

+0.5%

Cash

30.2M USD

44.3M USD

+46.7%

Shares outstanding

44.6M

45.0M

+1.0%

Key ratios

FY 2023

FY 2024

FY 2025

Change

Gross margin

52.6%

55.1%

55.4%

▲ 0.3 pts

Operating margin

-298.9%

-69.5%

-71.5%

▼ 2.0 pts

Net margin

-367.6%

-84.1%

-73.0%

▲ 11 pts

Return on assets (ROA)

-40.1%

-36.6%

-22.3%

▲ 14 pts

Return on equity (ROE)

—

-25.5%

—

Free cash flow margin

-273.8%

-79.3%

-56.1%

▲ 23 pts

Current ratio

9.77×

6.29×

8.66×

▲ 38%

Quick ratio

9.65×

5.66×

7.96×

▲ 41%